Special Issue

SARS-CoV-2 Innate and Adaptive Immune Responses

Message from the Guest Editors

In the present issue, we will focus on studies aiming at: -Innate immune response against coronaviruses, also including ssRNA viruses belonging to other families of viruses, PRR and PAMPS identification, inflammatory response and its regulation, and virus escape strategies. - Adaptive immune responses for vaccines development against anti-SARS-CoV-2 and new strategies for vaccine development. - Tropism of coronaviruses, including the role of glycosylation. - Biochemical, structural and functional characterization of SARS-CoV-2 gene products.

Guest Editors

Prof. Dr. Elmostafa Bahraoui

Institut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France

Dr. Remi Planes

IPBS, CNRS-Université Toulouse III, CNRS Toulouse, France

Deadline for manuscript submissions

closed (30 April 2022)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/84051

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34

mdpi.com/journal/ viruses

viruses@mdpi.com





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

